YiChang HEC ChangJiang Pharmaceutical Co., Ltd. provided group earnings guidance for the year ended 31 December 2023. For the year, the Group is expected to record a revenue of approximately RMB 6,295 million, representing an increase of approximately 68.09% as compared to the revenue of approximately RMB 3,745 million in the corresponding period of last year. The Group is expected to record a profit before tax between approximately RMB 2,027 million and RMB 2,227 million, representing an increase of approximately 5,097.44% to 5,610.26% as compared to the profit before tax of approximately RMB 39 million in the corresponding period of last year and the Group is expected to record a net profit attributable to the parent company between approximately RMB 1,900 million and RMB 2,100 million, representing an increase of approximately 2,367.53% to 2,627.27% as compared to the net profit attributable to the parent company of approximately RMB 77 million in the corresponding period of last year; Such expected increase is mainly attributable to the gradual improvement in socio-economic performance, the normalization of flow of people and daily social activities.

It is further attributable to the fact that the Group had stepped up its effort in promoting academic research and brand building during the year, increasing the brand awareness of Kewei, one of the Group's core products, and satisfactory performance of its other business pipelines and that the overall business has reflected trend of common development of multiple product lines.